Lundbeck suffers a setback in its attempts to promote the use of Rexulti, which is already among the company's best-selling products, reads the pharmaceutical company's Q2 report released Wednesday morning.
According to the report, a phase II trial of Rexulti didn't achieve the desired results as a possible treatment for borderline personality disorder, as the drug hasn't shown statistically significant separation from placebo after up to 12 weeks of treatment.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.